744 related articles for article (PubMed ID: 11463010)
1. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
[TBL] [Abstract][Full Text] [Related]
2. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
3. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
5. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
6. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.
Schulman S; Rhedin AS; Lindmarker P; Carlsson A; Lärfars G; Nicol P; Loogna E; Svensson E; Ljungberg B; Walter H
N Engl J Med; 1995 Jun; 332(25):1661-5. PubMed ID: 7760866
[TBL] [Abstract][Full Text] [Related]
7. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.
Schulman S; Lindmarker P
N Engl J Med; 2000 Jun; 342(26):1953-8. PubMed ID: 10874063
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
Farraj RS
Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
[TBL] [Abstract][Full Text] [Related]
10. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
[TBL] [Abstract][Full Text] [Related]
11. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
12. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
[TBL] [Abstract][Full Text] [Related]
13. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
[TBL] [Abstract][Full Text] [Related]
14. [The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism].
Yang P; Wu QH; Luo XY; Kou L; Chen Z; Zhang YY; Zhou H
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1762-5. PubMed ID: 19862981
[TBL] [Abstract][Full Text] [Related]
15. Duration of anticoagulant therapy after initial idiopathic venous thromboembolism.
Frazee LA; Chomo DL
Ann Pharmacother; 2003 Oct; 37(10):1489-96. PubMed ID: 14519045
[TBL] [Abstract][Full Text] [Related]
16. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
17. [Is a three-month therapy with warfarin adequate for effective therapy of patients after an episode of venous thrombosis].
Vorob'eva NM; Ermolina OV; Balakhonova TV; Dobrovol'skiĭ AB; Titaeva EV; Kirienko AI; Panchenko EP
Ter Arkh; 2008; 80(7):50-4. PubMed ID: 18763596
[TBL] [Abstract][Full Text] [Related]
18. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.
Kyrle PA; Minar E; Hirschl M; Bialonczyk C; Stain M; Schneider B; Weltermann A; Speiser W; Lechner K; Eichinger S
N Engl J Med; 2000 Aug; 343(7):457-62. PubMed ID: 10950667
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
20. Extended oral anticoagulant therapy after a first episode of pulmonary embolism.
Agnelli G; Prandoni P; Becattini C; Silingardi M; Taliani MR; Miccio M; Imberti D; Poggio R; Ageno W; Pogliani E; Porro F; Zonzin P;
Ann Intern Med; 2003 Jul; 139(1):19-25. PubMed ID: 12834314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
